Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

Diabetes specialist Novo Nordisk is feeling the heat from increasingly price conscious US payers. It needs next generation innovation and growth in emerging markets to keep ahead of competitors ...

Novo Nordisk's high-dose version of semaglutide boosts its weight-loss ability, but it still can't match its main rival in the obesity market. Skip to main content Tuesday 24 June ...